Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter Tolerability and Pharmacokinetic Study of Ascending Continuous Oral Doses of XT-0528 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

NCT05474859 is registered in ClinicalTrials.gov with Xenthera, Inc. as lead sponsor.

NCT NCT05474859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05474859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter Tolerability and Pharmacokinetic Study of Ascending Continuous Oral Doses of XT-0528 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Lead sponsor
Xenthera, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2024
Completion date
June 30, 2028
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic solid tumor